A post copied from ihub, Fletch dadofmarcmax

New Post Public Reply Private Reply Replies (5) Message Board
fletch Drano #876
666
A post copied from ihub,
Fletch

dadofmarcmax Wednesday, 09/26/18 01:59:51 PM
Re: None 0
Post # of 166985
Why does Anavex 2-73 have effects on seemingly different neurodegenerative disorders? What makes it so special?

Approximately 3 years ago, after I sold off all of my NVIV (with a healthy gain), I bought AVXL and, over time, have steadily added to my shares outside of a sell off of some in 2017 that I bought back earlier this year.

I started posting here in 2015- at that time after a bit of DD on the background science (see Hashimoto et al on PubMed searching of "chronic neuroinflammation and sigma 1 receptor" and related articles) - I understood that attacking the primary pathophysiological mechanism to many (if not most) neurodegenerative disorders - the nebulous chronic neuroinflammation - will be the key to solving the mystery of neurodegenerative disorders in general.

While the "amyloid hypothesis" was a good start at solving the mystery - it only seemed to address one aspect of a multifaceted neuroinflammatory process. Clearance of protein aggregates, in essence, can help but only to a small degree initially before the other aspects of chronic neuroinflammation overload the overall complicated feedback loops involved.

2-73, I believe, acts to switch "off" the on/off mechanism that regulates inflammatory cascades. Hence - it seems to have "broad spectrum" potential for numerous, seemingly different, neurological disorders that all share the commonality of being related to a chronic neuroinflammatory pathophysiology.

I have written numerously about my believe in posts past but want to share with you a very interesting poster I came across today - for the science minded found here:

NEUROINFLAMMATION

The poster is divided between the left ("proinflammatory" and right ("antiinflammatory" .

LEFT: Aberrant synaptic pruning (? autism related, epilepsy related, genetic disorders related), Demyelination and Axonal Degeneration (MS, dementia(s), ALS, etc), Modulation of BBB Permeability/Immune Cell recruitment (multiple neurological and non-neurological immune related disorders) all occur with inflammation.

RIGHT: Immune-Mediated Aggregate Removal, Cellular Repair and Regeneration - ("restoration of cellular homeostasis" occur once the inflammatory switch is turned off - allowing for body self healing, so to speak.

The past 2 years with silence and minimal information has been frustrating but with the little tidbits we have been getting, nothing has changed from the standpoint that - the scientific basis for 2-73's activity is still yet to be refuted. Now - big presentations lie ahead of us with this CTAD, in my opinion, being THE MAJOR PRESENTATION that we have been waiting for since 2015. This CTAD, in my opinion, will be the herald event that starts the flow away from "amyloid hypothesis" and moves it towards the "restoring of cellular homeostasis". Anavex, in my opinion, will be the first to take the lead.

You may call this hype - I call this studied common sense.

Of course, this is all my own opinion. Biostockclub, sokol, nidan, falconer, ffrol (yes, him) and plenty other posters here all are seemingly on the same page of thought as I am, at present.

Science is slow, changing the course of scientific thought is even slower but when change happens, it will be sudden, it will be quick and it will be all-encompassing.

Perhaps this is why we have been/are being held down for so long. Too much money and vested interest from very wealthy and very influential players in this "game" will lose too much when the change will happen. It WILL be Sudden and unexpected and unlikely to occur exactly on the day of CTAD.

The symphony starts at CTAD but there are 4 movements in this one - the fun starts at the end of the symphony.

Holding on tight!

As usual - this is all in my own opinion.

https://investorshub.advfn.com/boards/read_ms...=143816865

Anavex Life Sciences Corp. (AVXL) Stock Research Links

AVXL Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tuya Smart: AI Powers New Energy Wave at COP31

Updated Category News Views 0

Tuya Smart's Bold Move at COP31 Tuya Smart, a name you don't want to ignore in the world of energy innovation, made a commanding appearance at COP31. Their message was loud and clear: as the climate gets harsher, they're not just sitting around waiting for the next storm. They're arming households with AI-driven solutions. AI-Powered Energy Management Takes Center Stage...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 51

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 44

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 493

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 326

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 349

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
SOBER CAFFEINE™: Modern Energizer Without the Bull

Updated Category News Views 11

Shed the Cans and Embrace Convenience I'm sure you've had a run-in with the standard energy drink routine. You know, the massive cans, a gut punch of sugar, and the inevitable crash that follows? Sobriety Supplements LLC decided enough is enough and rolled out something that just makes sense—SOBER CAFFEINE™ capsules. This little pill is a godsend for folks sick of...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 187

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 483

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 197

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading

Top 5 Most Recently Viewed Articles

Ventas to Showcase Investment Strategy at Real Estate Conference

Updated Category News Views 44

Ventas Engages Investors at Upcoming Conference Ventas, Inc. (NYSE: VTR) is gearing up to take part in significant investor meetings at the BofA Securities 2024 Global Real Estate Conference. This event presents a valuable chance for the company to connect with investors and share insights about its strategic direction and business model. Event Details and Participation...

Continue Reading
BioLineRx Explores Synergy in Ovarian Cancer Treatment

Updated Category News Views 151

New Hope on the Ovarian Cancer Front Every so often, something comes along and makes you stop and think—could this be the game-changer in the making? Well, what BioLineRx Ltd. (NASDAQ: BLRX) and Hemispherian AS just dropped at the ESMO 2026 feels a bit like that silver lining for folks fighting the uphill battle against homologous recombination (HR)-proficient ovarian...

Continue Reading
Analyst Ratings Show Confidence in Datadog and Others

Updated Category News Views 80

Recent Upgrades by Top Analysts Leading financial analysts from Wall Street have adjusted their outlooks on several prominent companies, reflecting a more optimistic market sentiment. Upgrades often signify increased confidence in a company's performance and present potential investment opportunities for savvy investors. Here, we delve into some of the standout upgrades...

Continue Reading
Unpacking the Increased Short Interest in Ventas (NYSE: VTR)

Updated Category News Views 77

Understanding Ventas's Short Interest Surge Ventas recently recorded an uptick in its short percent of float, which now stands at 25.59% since the last report. This notable development means that 9.80 million shares are currently sold short, translating to 3.19% of all regular shares available for trading. Given the trading volume, it would take traders approximately 3.33...

Continue Reading
Precigen's PAPZIMEOS: 7-Year Exclusivity & Long-Term Success

Updated Category News Views 54

Precigen's Game-Changer: PAPZIMEOS Secures Seven-Year Exclusivity Here's how you carve out a solid niche in the biotech world: deliver some killer results and snag yourself seven years in the driver’s seat. That's exactly what Precigen (NASDAQ: PGEN) has done with their PAPZIMEOS therapy, which got the stamp of approval from the FDA as the first exclusive treatment for...

Continue Reading